Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Aug 22;8(9):84.
doi: 10.1038/s41408-018-0121-4.

Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies

Ing S Tiong  1 , John Reynolds  2 , Kenneth F Bradstock  3 , John F Seymour  4 , Andrew H Wei  5 ; Australasian Leukaemia & Lymphoma Group
Affiliations

Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies

Ing S Tiong et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Overall survival, relapse-free survival and cumulative hazard curves. a Overall survival comparing the AMLM7 and AMLM12 study cohorts. b Cumulative hazard of early deaths in the AMLM7 and AMLM12 study cohorts. c Cumulative hazard of early deaths in the AMLM7 cohort stratified by age groups. d Cumulative hazard of early deaths in the AMLM12 cohort stratified by age groups. e Overall survival by landmark analysis at 30 days in the AMLM7 and AMLM12 study cohorts. f Overall survival of patients receiving the common IcE consolidation chemotherapy. g Relapse-free survival in patients receiving the common IcE consolidation chemotherapy. h Overall survival in the AMLM12 study cohort receiving standard IcE consolidation chemotherapy, restricted to patients with >90 days of remission duration, stratified by allogeneic SCT in first remission and cytogenetic risk. Pairwise comparisons using log-rank test, with p-values adjusted by Benamini & Hochberg (BH) method
See this image and copyright information in PMC

References

    1. Derolf A. R., et al. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 2009, 113, 3666–3672. - PubMed
    1. Pulte D, Gondos A, Brenner H. Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century. Haematologica. 2008;93:594. doi: 10.3324/haematol.12304. - DOI - PubMed
    1. Bishop JF, et al. Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood. 1990;75:27–32. - PubMed
    1. Bishop JF, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87:1710–1717. - PubMed
    1. Bradstock KF, et al. A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood. 2005;105:481–488. doi: 10.1182/blood-2004-01-0326. - DOI - PubMed

MeSH terms